Hypercholesterolemia Partnering 2007-2013 provides understanding and access to the hypercholesterolemia partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of hypercholesterolemia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors hypercholesterolemia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.
Chapter 1 Introduction
Chapter 2 Trends in hypercholesterolemia partnering
2.2.Hypercholesterolemia partnering over the years
2.3. Bigpharma hypercholesterolemia dealmaking activity
2.4. Hypercholesterolemia partnering by deal type
2.5. Hypercholesterolemia partnering industry sector
2.6. Hypercholesterolemia partnering by stage of development
2.7. Hypercholesterolemia partnering by technology type
2.8. Disclosed financial deal terms for hypercholesterolemia partnering
2.8.1 Hypercholesterolemia headline values
2.8.2 Hypercholesterolemia upfront payments
2.8.3 Hypercholesterolemia milestone payments
2.8.4 Hypercholesterolemia royalty rates
3.2. Top hypercholesterolemia deals by value
3.3. Top hypercholesterolemia deals involving bigpharma